Canaccord downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $106, after the company entered into an agreement under which Merck (MRK) will acquire it for $107 per American depository share, or $10B.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Hold from Buy at Jefferies
- Video: Verona Pharma jumps after agreeing to be acquired by Merck for $10B
- Morning Movers: Starbucks climbs following reports of interest in China business
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal
- Verona Pharma Acquired by Merck for $10 Billion